# Obstructive Sleep Apnea

Diagnose suspected obstructive sleep apnea with appropriate sleep testing, prioritize symptom relief and blood-pressure control, and match PAP, mandibular advancement, weight management, positional therapy, or selected surgery to anatomy, severity, and treatment tolerance.

**Clinical question:** How should physicians confirm and individualize treatment for adult obstructive sleep apnea while addressing cardiometabolic and perioperative risk?

Updated: 2026-08-24T16:47:05.562191+00:00

## What matters in practice
- Use formal sleep testing rather than symptom assessment alone to establish OSA and guide treatment selection; diagnostic testing guidance is provided by the American Academy of Sleep Medicine. [8]
- PAP is an effective OSA treatment and improves symptoms, quality of life, and blood pressure, but randomized trials have not demonstrated reduced cardiovascular events or mortality with CPAP versus usual care. [8][19]
- Offer a custom mandibular advancement device when a patient prefers an oral appliance or cannot tolerate CPAP; it is an accepted alternative particularly for mild-to-moderate OSA. [13][14][21]
- Treat hypertension conventionally in patients with OSA, add weight loss for overweight or obesity, and use CPAP primarily for OSA control and potential blood-pressure benefit rather than cardiovascular event prevention. [8][19]
- Reserve upper-airway surgery or hypoglossal nerve stimulation for carefully selected patients who do not tolerate or respond adequately to noninvasive therapy, with anatomic assessment guiding procedural planning. [13][14]

## Confirm OSA with sleep testing before selecting therapy

Testing should establish the sleep-breathing disorder and provide a baseline for treatment response.

Order diagnostic sleep testing when the history and examination raise concern for clinically important OSA; the American Academy of Sleep Medicine diagnostic guideline addresses testing strategy for adults. [8] In patients with cardiovascular disease or hypertension, identify OSA as a potential contributor to elevated blood pressure and symptom burden, but do not treat a screening result as a diagnostic endpoint. [8][19]

Use the diagnostic study to distinguish obstructive events from other sleep-disordered breathing patterns before choosing PAP mode, oral appliance therapy, or an upper-airway intervention. Reassess for alternative explanations of daytime sleepiness, impaired function, or nocturnal symptoms when sleep testing does not establish clinically relevant OSA. [8][19]

Document blood pressure, body weight, sleepiness-related functional risk, and cardiovascular comorbidity at diagnosis because these parameters affect treatment goals. Moderate-to-severe OSA is associated with hypertension, cardiovascular events, and mortality; severe OSA is also associated with increased all-cause mortality. [8][19]
- Prioritize prompt testing when sleepiness creates driving or occupational safety risk; OSA is associated with road traffic accidents. [5]
- In resistant hypertension, assess for OSA because CPAP has shown blood-pressure reductions in this subgroup. [8]
- Before elective surgery, communicate known or suspected OSA to the perioperative team because postoperative respiratory complications are a recognized concern in surgical patients at high OSA risk. [6]

*Clinical features that change the diagnostic and management objective in OSA. [5][6][8][19]*

| Clinical context | Decision implication | Immediate next step |
| --- | --- | --- |
| Excessive sleepiness with driving or work-safety exposure | Focus treatment on symptom control and accident-risk reduction; OSA is associated with road traffic accidents. [5] | Expedite diagnostic sleep evaluation and address safety-sensitive activities pending effective treatment. [5] |
| Resistant hypertension | OSA may contribute to blood-pressure elevation; CPAP can reduce BP in some patients with resistant hypertension. [8] | Confirm OSA, continue guideline-directed antihypertensive therapy, and assess PAP use and BP response. [8] |
| Established cardiovascular disease without prominent sleepiness | PAP may improve OSA-related symptoms and BP, but randomized trials have not shown prevention of cardiovascular events or mortality. [8][19] | Set treatment goals around OSA control, symptoms, quality of life, and BP rather than promising event reduction. [8][19] |
| Upcoming surgery or postoperative hypoxemia risk | OSA risk is relevant to perioperative respiratory complications. [6] | Flag OSA risk for anesthesia and postoperative monitoring planning. [6] |

## Use PAP as the principal noninvasive treatment and measure adherence

Therapy should target airway obstruction, symptoms, functional impairment, and relevant blood-pressure burden.

Offer positive airway pressure therapy as the principal noninvasive treatment for diagnosed OSA when the patient can use it. PAP effectively treats OSA, while CPAP can eliminate recurrent hypoxia and reduce nocturnal blood pressure and heart rate. [8][12] At initiation, establish a practical adherence plan that addresses mask tolerance, nasal symptoms, pressure comfort, sleep schedule, and device-download review.

At follow-up, assess patient-reported sleepiness, functional improvement, adverse effects, residual device-reported events, and actual nightly use rather than assuming efficacy from prescription alone. The association between hours of CPAP use and improved insulin sensitivity in randomized data supports prioritizing sustained nightly exposure when metabolic outcomes are relevant. [17]

For hypertension, continue antihypertensive medication rather than substituting CPAP for standard blood-pressure treatment. Weight loss combined with CPAP can reduce BP in adults with overweight or obesity, and some studies show BP reduction with CPAP in resistant hypertension. [8] Do not represent CPAP as established secondary prevention for cardiovascular events: randomized comparisons of CPAP with usual care have not shown reductions in mortality, cardiovascular events, or kidney events. [19]
- Use symptom change, device-use data, and BP trend as separate outcomes; improvement in one does not establish improvement in all three. [8][17][19]
- Escalate adherence troubleshooting before abandoning PAP when the barrier is interface discomfort, nasal intolerance, or irregular sleep timing; CPAP adherence is clinically consequential. [9][17]
- For patients with overweight or obesity, pair OSA therapy with a structured weight-management intervention rather than presenting PAP as a substitute for weight loss. [7][8][17]

### Cardiometabolic expectations

Explain the treatment target precisely: CPAP improves OSA control and may improve blood pressure, insulin sensitivity, symptoms, and quality of life, but evidence does not establish that CPAP prevents cardiovascular events in unselected cardiovascular populations. [8][17][19][20] This distinction is especially important when an asymptomatic patient is considering treatment primarily for cardiovascular risk reduction.

*Outcome-directed follow-up after PAP initiation. [8][17][19]*

| Follow-up domain | What to review | How it changes management |
| --- | --- | --- |
| OSA control | PAP tolerance and device-use information. [8][17] | Troubleshoot interface, pressure comfort, and sleep schedule when effective use is limited. [9][17] |
| Symptoms and function | Daytime sleepiness, quality of life, and safety-sensitive impairment. [5][19] | Continue or modify therapy based on clinically meaningful functional response. [5][19] |
| Blood pressure | Office or out-of-office BP trend, particularly in resistant hypertension. [8] | Maintain antihypertensive therapy; use PAP and weight loss as adjunctive BP strategies. [8] |
| Cardiovascular prevention | Patient expectations regarding myocardial infarction, stroke, and mortality. [19][20] | Do not promise event or mortality reduction from CPAP based on current randomized evidence. [19] |

## Match alternatives to PAP intolerance, patient preference, anatomy, and severity

Non-PAP therapy is appropriate when it can provide an effective and durable alternative for the individual patient.

Offer a mandibular advancement device to adults with OSA who prefer oral-appliance therapy or cannot tolerate CPAP. ACP recommends mandibular advancement devices as an alternative to CPAP in diagnosed OSA, and professional guidance supports oral appliances for patients who prefer them or are CPAP-intolerant. [13][21] Custom devices fitted by a qualified dentist outperform off-the-shelf appliances and should be physician-prescribed. [14]

Mandibular advancement devices are most commonly used for mild-to-moderate OSA or when CPAP is not tolerated, although response is not uniform across severity categories. [14][21] Reassess symptoms and objective treatment response after device titration; do not infer control from perceived snoring reduction alone. Oral appliances can cause myofascial discomfort and excess salivation, which should prompt dental adjustment rather than automatic discontinuation. [14]

Use positional therapy when testing and clinical pattern suggest positional OSA and when a positional strategy is acceptable to the patient. Positional OSA occurs even in severe disease, and lateral-position approaches may be particularly relevant when obstruction is tongue-base predominant. [1][2] Confirm that the intervention controls the patient’s documented sleep-disordered breathing burden rather than relying solely on subjective improvement.

Recommend weight management for adults with overweight or obesity as a disease-modifying adjunct to airway therapy. Weight loss and lifestyle interventions improve OSA severity, and weight loss combined with CPAP can reduce BP. [7][8][17] Bariatric surgery is among available OSA treatment approaches for selected patients with obesity, but it should not be presented as a guaranteed cure of OSA. [7][14]
- Choose a custom mandibular advancement device rather than an over-the-counter appliance when selecting oral-appliance therapy. [14]
- Refer to a qualified dentist for fitting and longitudinal dental assessment of a mandibular advancement device. [14]
- Use a patient’s preference and ability to adhere to therapy as major selection variables; oral appliances may have greater overall adherence than CPAP despite less predictable physiologic efficacy. [14][22]
- Address alcohol and sedative exposure when pharyngeal collapse is a concern; abstinence from alcohol and sedatives is advised because they can predispose to sleep-related pharyngeal collapse. [18]

*Selection of non-PAP OSA therapies. [7][13][14][18][21][22]*

| Option | Best-supported role | Key tradeoff or monitoring need |
| --- | --- | --- |
| Custom mandibular advancement device | Alternative for diagnosed OSA when the patient prefers it or cannot tolerate CPAP; commonly used for mild-to-moderate OSA. [13][14][21] | Requires physician prescription and qualified dental fitting; monitor for myofascial discomfort and salivation. [14] |
| Positional therapy | Consider when testing identifies positional OSA or anatomy suggests position-responsive tongue-base obstruction. [1][2] | Verify clinical and objective response because positional dependence can occur even in severe OSA. [1] |
| Weight management | Adjunct for OSA in overweight or obesity; may improve OSA severity and BP when combined with CPAP. [7][8][17] | Does not replace reassessment of residual OSA or PAP/oral-appliance need. [7][14] |
| Avoidance of alcohol and sedatives | Adjunctive measure when these exposures may worsen pharyngeal collapse. [18] | Review medication necessity and balance changes against psychiatric, pain, or withdrawal risks. [18] |

## Use anatomic evaluation to select surgery or hypoglossal nerve stimulation

Procedural therapy is generally considered after inadequate response to, or intolerance of, noninvasive treatment.

Refer patients with persistent clinically consequential OSA despite noninvasive therapy, or with treatment-limiting PAP intolerance, for sleep-surgery evaluation when an anatomic target is plausible. Available surgical approaches include nasal septoplasty, adenotonsillectomy, uvulopalatoplasty, and maxillomandibular advancement; multilevel surgery is used when obstruction or collapse occurs at multiple levels. [14]

Use drug-induced sleep endoscopy and upper-airway assessment to characterize the site and pattern of collapse when planning targeted procedural therapy. Upper-airway collapse on drug-induced sleep endoscopy is relevant to surgical and hypoglossal nerve stimulation selection, and preoperative predictors of hypoglossal nerve stimulation response have been described. [1][2] Do not use Mallampati grade alone to choose a procedure; it may suggest anatomy but does not replace sleep-study and endoscopic assessment. [1][2]

Consider hypoglossal nerve stimulation as a surgical alternative for selected OSA patients who do not tolerate or respond adequately to other treatment approaches. Selection requires evaluation of upper-airway collapse pattern and individualized discussion of surgical risks, expected efficacy, device management, and alternatives. [1][2][14]

Position nasal surgery appropriately: septoplasty may improve PAP delivery rather than serve as stand-alone curative treatment for OSA. [14] For any airway surgery, counsel that procedures are rarely curative and may be best incorporated into a multimodal plan with objective post-treatment reassessment. [14]
- Escalate to procedural assessment after documenting the specific reason PAP or oral-appliance therapy failed: intolerance, inadequate physiologic response, inadequate symptom response, or anatomic obstruction. [13][14]
- Use multilevel surgical planning only when multiple obstruction levels are identified. [14]
- Plan postoperative monitoring carefully in patients with OSA because perioperative and anesthesia-related respiratory complications remain relevant. [1][6][14]

*Procedural options for patients with inadequately controlled OSA after noninvasive therapy. [1][2][14]*

| Approach | Selection principle | Counseling point |
| --- | --- | --- |
| Nasal septoplasty | Consider when nasal obstruction impairs PAP delivery or is a component of multilevel obstruction. [14] | Usually adjunctive rather than curative for OSA. [14] |
| Multilevel upper-airway surgery | Use when evaluation identifies multiple levels of obstruction or collapse. [14] | Pain and anesthesia-related complications are relevant; objective reassessment is needed because cure is uncommon. [14] |
| Maxillomandibular advancement | Consider as an anatomic surgical option within a specialist-directed airway plan. [1][14] | Preoperative anatomy affects expected response; do not select solely from bedside airway grading. [1][2] |
| Hypoglossal nerve stimulation | Consider for selected patients with inadequate tolerance or response to other therapies after collapse-pattern evaluation. [1][2][14] | Requires surgical implantation and individualized assessment of expected response. [1][2] |

## Reassess efficacy after every material change in therapy or risk profile

OSA treatment is durable only when symptoms, adherence, and cardiometabolic goals are reviewed longitudinally.

After PAP, oral-appliance titration, weight loss intervention, positional treatment, or surgery, reassess symptoms, functional safety, treatment tolerance, and objective control of sleep-disordered breathing. This is particularly important when a patient reports improved snoring but retains sleepiness, hypertension, or device intolerance. [5][8][14][21]

Monitor BP separately from OSA symptoms. OSA therapy may improve BP, especially with CPAP in resistant hypertension and with combined CPAP plus weight loss in overweight or obesity, but antihypertensive treatment remains necessary when indicated. [8] If BP remains resistant despite apparent OSA control, evaluate adherence and continue the broader secondary-hypertension and medication assessment.

Revisit treatment choice when body weight changes, a dental appliance causes adverse effects, PAP use declines, a positional strategy fails, or postoperative symptoms persist. OSA management frequently requires combination therapy—such as weight management plus PAP, or nasal intervention to facilitate PAP—rather than a single permanent intervention. [7][8][14][17]
- Document whether the patient’s primary target is sleepiness, driving safety, BP, treatment tolerability, or reduction of objectively documented obstruction. [5][8][19]
- Use shared decision-making when cardiovascular prevention is the main motivation because symptomatic and BP benefits are better established than event prevention with CPAP. [8][19][20]
- Continue to assess alcohol and sedative exposure when residual upper-airway collapse or worsening OSA is suspected. [18]

*Triggers for OSA treatment reassessment. [7][8][14][17][21]*

| Trigger | Interpretation | Action |
| --- | --- | --- |
| Persistent sleepiness or functional impairment | May indicate inadequate OSA control, insufficient PAP exposure, or another cause of symptoms. [5][8] | Review objective therapy use and repeat sleep-focused evaluation as clinically indicated. [8] |
| PAP intolerance | Treatable interface, pressure-comfort, nasal, or sleep-schedule barriers may be present. [9][17] | Troubleshoot PAP; consider a custom mandibular advancement device or procedural evaluation when intolerance persists. [13][14][21] |
| Weight gain or substantial weight loss | Upper-airway collapsibility and OSA burden may change with weight. [7][23] | Reassess the adequacy of the existing treatment plan. [7][14] |
| Oral-appliance adverse effects | Myofascial discomfort or excess salivation can limit adherence. [14] | Arrange dental reassessment and adjust the device; verify ongoing treatment response. [14][21] |

## References
1. Confidential: For Review Only — www.bmj.com — https://www.bmj.com/sites/default/files/attachments/bmj-article/pre-pub-history/13-may-2025_bmj-2025-084539.r1_proof_hi.pdf
2. 1 / 94 1 May 13th, 2025 2 Dr. Di Wang 3 Clinical Editor, The ... — www.bmj.com — https://www.bmj.com/sites/default/files/attachments/bmj-article/pre-pub-history/13-may-2025_response_letter-20250513-r1.pdf
3. Longer-term impacts of the COVID-19 pandemic on ... — bmjopenrespres.bmj.com — https://bmjopenrespres.bmj.com/content/11/1/e002476
4. Supplementary appendix — www.thelancet.com — https://www.thelancet.com/cms/10.1016/S2213-2600(25)00002-5/attachment/d03970b7-47f4-4575-9665-952d9f2a3698/mmc1.pdf
5. Adult obstructive sleep apnoea — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60734-5/abstract
6. Effects of obstructive sleep apnoea risk on postoperative ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/6/1/e008436
7. Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome | Signal Transduction and Targeted Therapy — www.nature.com — https://www.nature.com/articles/s41392-023-01496-3
8. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356
9. The association between irregularity in sleep-wake rhythm and CPAP adherence | npj Biological Timing and Sleep — www.nature.com — https://www.nature.com/articles/s44323-024-00001-5
10. Automatic prediction of obstructive sleep apnea in patients with temporomandibular disorder based on multidata and machine learning | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-024-70432-4
11. General dental practitioners' knowledge and opinions of ... — www.nature.com — https://www.nature.com/articles/s41415-021-3573-z
12. Sleep Apnea and Cardiovascular Disease | Circulation — www.ahajournals.org — https://www.ahajournals.org/doi/full/10.1161/circulationaha.107.189420?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=sleep+apnea+and+cardiovascular+disease&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT
13. Management of Obstructive Sleep Apnea in Adults — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-159-7-201310010-00704
14. Obstructive Sleep Apnea and Cardiovascular Disease — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000000988
15. Obstructive Sleep Apnea in Cardiovascular Disease — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/JAHA.118.010440?discount=LIFETIME
16. Treatment of Anemia in Patients With Heart Disease — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-159-11-201312030-00009
17. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2016.11.069
18. Sleep Apnea and Cardiovascular Disease — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2008.05.002
19. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2026.03.056
20. Sleep Disordered Breathing and Cardiovascular Disease: JACC State-of-the-Art Review — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2021.05.048
21. Prediction of oral appliance treatment outcomes in obstructive sleep apnea: A systematic review - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1087079215001586
22. Continuous positive airway pressure versus mandibular advancement device in the treatment of obstructive sleep apnea: a systematic review and meta-analysis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1389945720301271
23. Anatomical determinants of upper airway collapsibility in obstructive sleep apnea: A systematic review and meta-analysis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S108707922200154X
24. Cardiovascular effects of oral appliance therapy in obstructive sleep apnea: A systematic review and meta-analysis — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1087079217301363

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.